Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10600734 | 0.98 | OPRD1 (0.57) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL2539292 | 0.93 | OPRD1 (0.65) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Hydrochloric Acid SCHEMBL2310717 | 0.91 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Bromide SCHEMBL7444095 | 0.91 | OPRD1 (0.63) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL2457390 | 0.89 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Hydrochloric Acid SCHEMBL7647391 | 0.87 | OPRD1 (0.59) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Bromide SCHEMBL10598951 | 0.87 | OPRD1 (0.59) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL9631918 | 0.86 | OPRD1 (0.58) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL10599177 | 0.86 | OPRD1 (0.58) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL21384863 | 0.84 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1058780-A | Has the active thiazolidine carboxylic acid amides derivative of anti-allergy, their preparation and application | SANKYO CO (JP) | 1992-02-19 | — | — | CN | claimed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3768684-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
| US-5232924-A | Cardiovascular disorders | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0536419-A1 | TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1993-04-14 | — | — | EP | disclosed |
| CN-1066849-A | Three ring triazolo derivatives, its Manufacturing approach and use | TORAY INDUSTRIES (JP) | 1992-12-09 | — | — | CN | disclosed |
| CN-1058780-A | Has the active thiazolidine carboxylic acid amides derivative of anti-allergy, their preparation and application | SANKYO CO (JP) | 1992-02-19 | — | — | CN | disclosed |
| US-5079249-A | Serotine antagonists at 5-HT2 level, antiallergens, antihistamines | ADIR ET COMPAGNIE (FR) | 1992-01-07 | — | — | US | disclosed |
| US-5071847-A | BIS (ARYL) ALKENE COMPOUNDS OF HOMOPIPERIDINES USEFUL AS SEROTONIN-ANTAGONISTS | ADIR ET COMPAGNIE (FR) | 1991-12-10 | — | — | US | disclosed |
| US-5028607-A | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 1991-07-02 | — | — | US | disclosed |
| EP-0401707-A1 | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885OPRM1 860/4885OPRK1 3335/4885 |
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | OPRD1 1395/4885OPRM1 549/4885OPRK1 1592/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885OPRM1 860/4885OPRK1 3335/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | OPRD1 1395/4885OPRM1 549/4885OPRK1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.